Immunomodulatory drugs in multiple myeloma

References

• Kumar SK, Rajkumar SV, Dispenzieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5), 2516–2520 (2008).
   PubMed Web of Science ®Google Scholar
• Tricot GJ. New insights into role of microenvironment in multiple myeloma. Int. J. Hematol. 76(Suppl. 1), 334–336 (2002).
   PubMed Web of Science ®Google Scholar
• Vacca A, Ria R, Ribatti D et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 88(2), 176–185 (2003).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N. Engl. J. Med. 364(11), 1046–1060 (2011).
   PubMed Web of Science ®Google Scholar
• Shannon EJ, Miranda RO, Morales MJ, Hastings RC. Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand. J. Immunol. 13(6), 553–562 (1981).
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 4(4), 314–322 (2004).
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol. 163(1), 380–386 (1999).
   PubMed Web of Science ®Google Scholar
• Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell. Immunol. 162(2), 248–255 (1995).
   PubMed Web of Science ®Google Scholar
• Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356(6370), 607–609 (1992).
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Hideshima T, Catley LP et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103(5), 1787–1790 (2004).
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98(1), 210–216 (2001).
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Roncali L et al. Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 87(3), 503–508 (1994).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Podar K, Tai YT, Davies FE et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98(2), 428–435 (2001).
   PubMed Web of Science ®Google Scholar
• Gupta D, Treon SP, Shima Y et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15(12), 1950–1961 (2001).
   PubMed Web of Science ®Google Scholar
• Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93(5), 1658–1667 (1999).
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99(12), 4525–4530 (2002).
   PubMed Web of Science ®Google Scholar
• Breitkreutz I, Raab MS, Vallet S et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22(10), 1925–1932 (2008).
   PubMed Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T et al. Identification of a primary target of thalidomide teratogenicity. Science 327(5971), 1345–1350 (2010).
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118(18), 4771–4779 (2011).
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341(21), 1565–1571 (1999).
   PubMed Web of Science ®Google Scholar
• van Rhee F, Dhodapkar M, Shaughnessy JD Jr et al. First thalidomide clinical trial in multiple myeloma: a decade. Blood 112(4), 1035–1038 (2008).
   PubMed Web of Science ®Google Scholar
• Neben K, Moehler T, Benner A et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin. Cancer Res. 8(11), 3377–3382 (2002).
   PubMed Web of Science ®Google Scholar
• Hus M, Dmoszynska A, Soroka-Wojtaszko M et al.; Polish Multiple Myeloma Study Group. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 86(4), 404–408 (2001).
   PubMed Web of Science ®Google Scholar
• Wu KL, Helgason HH, van der Holt B et al. Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas. Leukemia 19(1), 143–145 (2005).
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Hoffmann F et al. A systematic review of Phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 132(5), 584–593 (2006).
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96(9), 2943–2950 (2000).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Giaccone L, Bertola A et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86(4), 399–403 (2001).
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin. Hematol. 40(4 Suppl. 4), 3–7 (2003).
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Haematol. 121(5), 768–771 (2003).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Rosiñol L, Hussein M et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J. Clin. Oncol. 26(13), 2171–2177 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar S, Giralt S, Stadtmauer EA et al.; International Myeloma Working Group. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 114(9), 1729–1735 (2009).
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P et al.; Bologna 2002 study. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106(1), 35–39 (2005).
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda VH, Domínguez-Martínez VJ. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? Eur. J. Haematol. 77(3), 239–244 (2006).
   PubMedGoogle Scholar
• Macro M, Divine M, Uzunhan Y et al. Dexamethasone + thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. ASH Annual Meeting Abstracts 108(11), Abstract 57 (2006).
   Google Scholar
• Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N. Engl. J. Med. 354(10), 1021–1030 (2006).
   PubMed Web of Science ®Google Scholar
• Cavo M, Di Raimondo F, Zamagni E et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. J. Clin. Oncol. 27(30), 5001–5007 (2009).
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, van der Holt B, Zweegman S et al.; Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized Phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115(6), 1113–1120 (2010).
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Davies FE, Gregory WM et al.; National Cancer Research Institute Haematological Oncology Clinical Studies Group. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 97(3), 442–450 (2012).
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Richardson PG et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101(6), 2377–2380 (2003).
   PubMed Web of Science ®Google Scholar
• Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide–dexamethasone for previously untreated multiple myeloma. Hematology 12(3), 235–239 (2007).
   PubMed Web of Science ®Google Scholar
• Pineda-Roman M, Zangari M, van Rhee F et al. VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 22(7), 1419–1427 (2008).
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F et al.; GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised Phase 3 study. Lancet 376(9758), 2075–2085 (2010).
   PubMed Web of Science ®Google Scholar
• Cavo M, Pantani L, Petrucci MT et al.; GIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto) Italian Myeloma Network. Bortezomib–thalidomide–dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 120(1), 9–19 (2012).
   PubMed Web of Science ®Google Scholar
• Fayers PM, Palumbo A, Hulin C et al.; Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118(5), 1239–1247 (2011).
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Hulin C et al.; Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370(9594), 1209–1218 (2007).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Corradini P et al.; GIMEMA–Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA–Italian Multiple Myeloma Network. J. Clin. Oncol. 25(28),4459–4465 (2007).
   PubMed Web of Science ®Google Scholar
• Mateos MV, Richardson PG, Schlag R et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the Phase III VISTA trial. J. Clin. Oncol. 28(13), 2259–2266 (2010).
   PubMed Web of Science ®Google Scholar
• Kapoor P, Rajkumar SV, Dispenzieri A et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia 25(4), 689–696 (2011).
   PubMed Web of Science ®Google Scholar
• Barosi G, Merlini G, Billio A et al. SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Ann. Hematol. 91(6), 875–888 (2012).
   PubMed Web of Science ®Google Scholar
• Ludwig H, Hajek R, Tóthová E et al. Thalidomide–dexamethasone compared with melphalan–prednisolone in elderly patients with multiple myeloma. Blood 113(15), 3435–3442 (2009).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Sezer O, Kyle R et al.; IMWG. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23(10), 1716–1730 (2009).
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R et al.; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357(21), 2133–2142 (2007).
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M et al.; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357(21), 2123–2132 (2007).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100(9), 3063–3067 (2002).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Blood E, Mitsiades CS et al. A randomized Phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108(10), 3458–3464 (2006).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A et al. Long-term follow-up on overall survival from the MM-009 and MM-010 Phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23(11), 2147–2152 (2009).
   PubMed Web of Science ®Google Scholar
• Wang M, Dimopoulos MA, Chen C et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112(12), 4445–4451 (2008).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13), 4050–4053 (2005).
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Gertz MA, Dispenzieri A et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin. Proc. 82(10), 1179–1184 (2007).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS et al.; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11(1), 29–37 (2010).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M et al.; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N. Engl. J. Med. 366(19), 1759–1769 (2012).
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5), 679–686 (2010).
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS et al.; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 20(9), 1467–1473 (2006).
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lacy MQ, Hayman SR et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a Phase 2 trial. Am. J. Hematol. 86(8), 640–645 (2011).
   PubMed Web of Science ®Google Scholar
• Kapoor P, Kumar S, Fonseca R et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 114(3), 518–521 (2009).
   PubMed Web of Science ®Google Scholar
• Kumar SK, Flinn I, Noga SJ et al. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: Phase 1 results from the multicenter EVOLUTION study. Leukemia 24(7), 1350–1356 (2010).
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Griffith KA, Reece DE et al. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a Phase 1/2 Multiple Myeloma Research Consortium trial. Blood 118(3), 535–543 (2011).
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Jayabalan DS, Christos PJ et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 111(3), 1101–1109 (2008).
   PubMed Web of Science ®Google Scholar
• Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H, Hibi T. Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer Res. 24(6), 3723–3730 (2004).
   PubMedGoogle Scholar
• Dispenzieri A, Rajkumar SV, Gertz MA et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin. Proc. 82(3), 323–341 (2007).
   PubMed Web of Science ®Google Scholar
• Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92(9), 3131–3136 (1998).
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lacy MQ, Dispenzieri A et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 118(6), 1585–1592 (2012).
   PubMed Web of Science ®Google Scholar
• Schey SA, Fields P, Bartlett JB et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. 22(16), 3269–3276 (2004).
   PubMed Web of Science ®Google Scholar
• Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br. J. Haematol. 141(1), 41–51 (2008).
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Hayman SR, Gertz MA et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27(30), 5008–5014 (2009).
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Hayman SR, Gertz MA et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 24(11), 1934–1939 (2010).
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Allred JB, Gertz MA et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 118(11), 2970–2975 (2011).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Larocca A, Carella A et al. A Phase I/II Study of Pomalidomide–Cyclophosphamide–Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide. Session 653. Presented at: 53rd Annual ASH Meeting. New Orleans, LA, USA, 10–13 December 2011.
   Google Scholar
• Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br. J. Haematol. 113(4), 1020–1034 (2001).
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Leyvraz S et al.; Inter-Groupe Francophone du Myélome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108(10), 3289–3294 (2006).
   PubMed Web of Science ®Google Scholar
• Spencer A, Prince HM, Roberts AW et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J. Clin. Oncol. 27(11), 1788–1793 (2009).
   PubMed Web of Science ®Google Scholar
• Ludwig H, Adam Z, Tóthová E et al. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica 95(9), 1548–1554 (2010).
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Gregory WM, Davies FE et al.; National Cancer Research Institute Haematological Oncology Clinical Studies Group. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119(1), 7–15 (2012).
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G et al.; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366(19), 1782–1791 (2012).
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366(19), 1770–1781 (2012).
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J. Support. Oncol. 1(3), 194–205 (2003).
   PubMedGoogle Scholar
• Chen C, Reece DE, Siegel D et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br. J. Haematol. 146(2), 164–170 (2009).
   PubMed Web of Science ®Google Scholar
• Figaro MK, Clayton W Jr, Usoh C et al. Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review. Am. J. Hematol. 86(6), 467–470 (2011).
   PubMed Web of Science ®Google Scholar
• Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N. Engl. J. Med. 354(19), 2079–2080 (2006).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA et al.; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2), 414–423 (2008).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavo M, Bringhen S et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a Phase III, open-label, randomized trial. J. Clin. Oncol. 29(8), 986–993 (2011).
   PubMed Web of Science ®Google Scholar
• Larocca A, Cavallo F, Bringhen S et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 119(4), 933–999; quiz 1093 (2012).
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21(9), 2035–2042 (2007).
   PubMed Web of Science ®Google Scholar
• Popat U, Saliba R, Thandi R et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol. Blood Marrow Transplant. 15(6), 718–723 (2009).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 86(1), 57–65 (2011).
   PubMed Web of Science ®Google Scholar